VIDEO: Win-win with denosumab as adjuvant therapy for post-menopausal breast cancerDecember 9, 2015Breast Cancer
ASH: Idelalisib plus standard therapy boosts survival in relapsed CLLDecember 9, 2015Leukemia, Myelodysplasia, Transplantation
SABCS: CREATE-X – Capecitabine is efficacious against residual HER2-negative breast cancerDecember 9, 2015Breast Cancer
VIDEO: High-intensity conditioning stands ground in MDS, AMLDecember 8, 2015Leukemia, Myelodysplasia, Transplantation
Upfront idelalisib carries high risk for acute liver toxicityDecember 8, 2015Leukemia, Myelodysplasia, Transplantation
Cigna CEO David Cordani: ACA marketplace is still in ‘version 1.0’December 8, 2015Practice Management
VIDEO: Top-line results from Tourmaline in multiple myeloma, plus ongoing trials and treatment selectionDecember 7, 2015Lymphoma & Plasma Cell Disorders
ASH: Rituximab add-on therapy ‘new standard’ in BCP-ALLDecember 7, 2015Leukemia, Myelodysplasia, Transplantation
Treatment delay linked with worse outcome for head and neck cancerDecember 7, 2015Head & Neck/Thyroid Cancers
ASH: Daratumumab and len/dex produce high response rates in refractory myelomaDecember 7, 2015Lymphoma & Plasma Cell Disorders
ASH: First-line ibrutinib beats standard chemo for CLL/SLL in older patientsDecember 7, 2015Lymphoma & Plasma Cell Disorders
.jpg)
